Clinical Trial Results. org Value of Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women:

Slides:

Advertisements

Similar presentations

Consensus and Recommendations for LDL-P. Brunzell et al. Diabetes Care (4): “Measurement of LDL cholesterol (the cholesterol within.

Advertisements

Summary Prepared by Melvyn Rubenfire, MD

Break the Fast: “Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control.

Change in Abdominal Obesity & Risk of Coronary Calcification Siamak Sabour, MD, MSc, DSc, PhD, Postdoc Clinical Epidemiologist Persian International Epidemiology.

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.

Clinical Trial Results. org Based on the Iron (Fe) and Atherosclerosis Study (FeAST) Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN;

Cholesterol quintile (mg/dL)

Nahal Mavaddat GP and Primary Care Research Unit School for Primary Care Research Self-Rated Health: Determinants and Outcomes.

Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.

Morteza Naghavi, M.D. Founder Society for Heart Attack Prevention and Eradication (SHAPE) SHAPE Guidelines Prevention of Fatal Cardiovascular Events (Heart.

Overly concerning and falsely reassuring?? FRAMINGHAM RISK FACTORS IN THE ED.

Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?

HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)

Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.

THE LIPID PANEL What are we missing? Robert St. Amant, MD, FAAFP Diplomate, American Board of Clinical Lipidology Baton Rouge General Medical Director,

Global impact of ischemic heart disease World Heart Federation, 2011.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.

Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.

The concept of Diabetes & CV risk: A lifetime risk challenge The Clinical Significance of LDL-Cholesterol: No Longer a Hypothesis? John J.P. Kastelein,

10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Clinical Trial Results. org Long-Term Prognosis Associated with Coronary Calcification Matthew J. Budoff, MD, Leslee J. Shaw, PhD, Sandy T. Liu, Steven.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.

ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.

Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Clinical Trial Results. org RAAVE Luis M. Moura, MD; Sandra F. Ramos, MSc; José L. Zamorano, MD, PhD; Isabel M. Barros, MD; Luis F. Azevedo, MD; Francisco.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention With Statins: ACC/AHA Risk-Based.

Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.

Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;

Are We There Yet ? Abdul H. Sankari, MD FACC FCCP.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events Journal conference Anand Rohatgi, M.D., Amit Khera, M.D., Jarett D. Berry, M.D., Edward.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Circulation. 2013;128: R4 이태인 / Prof. 우종신.

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Arabinda Mohan Bhattarai, MBBS, MD (Biochemistry) Asst Prof, NAIHS

Poster Number 2842 Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus. L. Durcan1, A.

Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?

AIM HIGH Niacin plus Statin to prevent vascular events

HDL cholesterol and cardiovascular risk Epidemiological evidence

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol by Allan.

HDL cholesterol and cardiovascular risk

C‐Reactive Protein Identifies Low‐Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancer–Norfolk Prospective Population.

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

Neil J. Stone et al. JACC 2014;63:

Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study Dr Danish Saleheen, PhD,

Baseline characteristics of HPS participants by prior diabetes

James H. O'Keefe, M.D., Carl J. Lavie, M.D., Ben D. McCallister, M.D.

Contemporary Evidence-Based Guidelines

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

Khurram Nasir et al. JACC 2015;66:

Stephen J. Nicholls, MBBS, PhD; E

Pamela E. Scott et al. JACC 2018;71:

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Presentation transcript:

Clinical Trial Results. org Value of Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study Karim El Harchaoui, MD; Wim A. van der Steeg, MD; Erik S. G. Stroes, MD, PhD; Jan Albert Kuivenhoven, PhD; James D. Otvos, PhD; Nicholas J. Wareham, MBBS, PhD; Barbara A. Hutten, PhD; John J.P. Kastelein, MD, PhD; Kay-Tee Khaw, MBBChir; S. Matthijs Boekholdt, MD, PhD Published in JACC February 6, 2007 Value of LDL Particle Number and Size as Predictors of CAD in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study

Clinical Trial Results. org The causal role of low-density lipoprotein (LDL) particles in the pathogenesis of coronary artery disease (CAD) is well established.The causal role of low-density lipoprotein (LDL) particles in the pathogenesis of coronary artery disease (CAD) is well established. Low-density lipoprotein cholesterol (LDL-C) content is used as a parameter to estimate LDL-associated CAD risk.Low-density lipoprotein cholesterol (LDL-C) content is used as a parameter to estimate LDL-associated CAD risk. The number of LDL particles (LDL-P) and the size has been proposed as a more reliable method reflecting atherogenicity of the LDL fraction. The number of LDL particles (LDL-P) and the size has been proposed as a more reliable method reflecting atherogenicity of the LDL fraction. The causal role of low-density lipoprotein (LDL) particles in the pathogenesis of coronary artery disease (CAD) is well established.The causal role of low-density lipoprotein (LDL) particles in the pathogenesis of coronary artery disease (CAD) is well established. Low-density lipoprotein cholesterol (LDL-C) content is used as a parameter to estimate LDL-associated CAD risk.Low-density lipoprotein cholesterol (LDL-C) content is used as a parameter to estimate LDL-associated CAD risk. The number of LDL particles (LDL-P) and the size has been proposed as a more reliable method reflecting atherogenicity of the LDL fraction. The number of LDL particles (LDL-P) and the size has been proposed as a more reliable method reflecting atherogenicity of the LDL fraction. Value of LDL Particle Number and Size as Predictors of CAD in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study: Background El Harchaoui et al. JACC Feb 6; 49 (5): 547 – 553.

Clinical Trial Results. org This study used nuclear magnetic resonance (NMR) spectroscopy to measure both LDL-P and LDL particle size.This study used nuclear magnetic resonance (NMR) spectroscopy to measure both LDL-P and LDL particle size. Associations were evaluated between LDL-P and LDL size, in comparison with LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) as traditional markers, as was risk of future CAD in apparently healthy men and women enrolled in a large prospective cohort with moderately elevated LDL-C.Associations were evaluated between LDL-P and LDL size, in comparison with LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) as traditional markers, as was risk of future CAD in apparently healthy men and women enrolled in a large prospective cohort with moderately elevated LDL-C. This study used nuclear magnetic resonance (NMR) spectroscopy to measure both LDL-P and LDL particle size.This study used nuclear magnetic resonance (NMR) spectroscopy to measure both LDL-P and LDL particle size. Associations were evaluated between LDL-P and LDL size, in comparison with LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) as traditional markers, as was risk of future CAD in apparently healthy men and women enrolled in a large prospective cohort with moderately elevated LDL-C.Associations were evaluated between LDL-P and LDL size, in comparison with LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C) as traditional markers, as was risk of future CAD in apparently healthy men and women enrolled in a large prospective cohort with moderately elevated LDL-C. Value of LDL Particle Number and Size as Predictors of CAD in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study: Background (cont.) El Harchaoui et al. JACC Feb 6; 49 (5): 547 – 553.

Clinical Trial Results. org Value of LDL Particle Number and Size as Predictors of CAD in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study: Study Design  Calculation of odds ratios for future CAD. Evaluation of LDL-P to improve upon prediction of CAD by Framingham risk score (FRS). Patients who developed a fatal or non-fatal CAD during follow-up n=1,003 Patients who developed a fatal or non-fatal CAD during follow-up n=1,003 Controls patients were those who remained free of CAD during follow-up n=1,885 Controls patients were those who remained free of CAD during follow-up n=1,885 25,663 patients aged years who were participants of the EPIC-Norfolk Study. 1,003 individuals were chosen who developed CAD during 6-year follow-up, matched for age, gender, and enrollment time with 1,885 controls. Nest Case-Control Study. Mean follow-up 6 years Exclusion Criteria: History of heart attack or stroke. No subjects were on statin treatment. 25,663 patients aged years who were participants of the EPIC-Norfolk Study. 1,003 individuals were chosen who developed CAD during 6-year follow-up, matched for age, gender, and enrollment time with 1,885 controls. Nest Case-Control Study. Mean follow-up 6 years Exclusion Criteria: History of heart attack or stroke. No subjects were on statin treatment. Matching El Harchaoui et al. JACC Feb 6; 49 (5): 547 – 553.

Clinical Trial Results. org For the univariate analysis, the magnitude of the predictive value of LDL-P (OR 2.0, 95% CI ) and non-HDL-C (OR 2.14, 95% CI ) were greater than that of LDL-C (OR 1.73, 95% CI ). For the univariate analysis, the magnitude of the predictive value of LDL-P (OR 2.0, 95% CI ) and non-HDL-C (OR 2.14, 95% CI ) were greater than that of LDL-C (OR 1.73, 95% CI ). However, the additional value of LDL-P was lost after adjustment for HDL-C and triglyceride levels. However, the additional value of LDL-P was lost after adjustment for HDL-C and triglyceride levels. Value of LDL Particle Number and Size as Predictors of CAD in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study: Odds Ratios for Future CAD El Harchaoui et al. JACC Feb 6; 49 (5): 547 – 553.

Clinical Trial Results. org In the large cohort of apparently healthy men and women, LDL-P and non-HDL-C were more closely associated than LDL cholesterol with the occurrence of future CAD.In the large cohort of apparently healthy men and women, LDL-P and non-HDL-C were more closely associated than LDL cholesterol with the occurrence of future CAD. After adjustment for HDL-C and triglycerides, LDL-P was no longer more predictive than LDL-C.After adjustment for HDL-C and triglycerides, LDL-P was no longer more predictive than LDL-C. In the large cohort of apparently healthy men and women, LDL-P and non-HDL-C were more closely associated than LDL cholesterol with the occurrence of future CAD.In the large cohort of apparently healthy men and women, LDL-P and non-HDL-C were more closely associated than LDL cholesterol with the occurrence of future CAD. After adjustment for HDL-C and triglycerides, LDL-P was no longer more predictive than LDL-C.After adjustment for HDL-C and triglycerides, LDL-P was no longer more predictive than LDL-C. Value of LDL Particle Number and Size as Predictors of CAD in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study: Summary El Harchaoui et al. JACC Feb 6; 49 (5): 547 – 553.

Clinical Trial Results. org These findings do not support routine use of LDL-P in CAD risk assessment strategies in primary prevention strategies.These findings do not support routine use of LDL-P in CAD risk assessment strategies in primary prevention strategies. However, recognition that patients with low HDL-C and/or high triglycerides often have elevated numbers of LDL particles without having elevated LDL-C may enable their LDL-related CAD risk to be managed more effectively.However, recognition that patients with low HDL-C and/or high triglycerides often have elevated numbers of LDL particles without having elevated LDL-C may enable their LDL-related CAD risk to be managed more effectively. These findings do not support routine use of LDL-P in CAD risk assessment strategies in primary prevention strategies.These findings do not support routine use of LDL-P in CAD risk assessment strategies in primary prevention strategies. However, recognition that patients with low HDL-C and/or high triglycerides often have elevated numbers of LDL particles without having elevated LDL-C may enable their LDL-related CAD risk to be managed more effectively.However, recognition that patients with low HDL-C and/or high triglycerides often have elevated numbers of LDL particles without having elevated LDL-C may enable their LDL-related CAD risk to be managed more effectively. Value of LDL Particle Number and Size as Predictors of CAD in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study: Summary El Harchaoui et al. JACC Feb 6; 49 (5): 547 – 553.